Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease
Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease
复制标题
DOI：
10.1053/j.ackd.2017.12.002
复制
发表时间：
2018-03-01
影响因子：
2.9
通讯作者：
Tuttle, Katherine R.
中科院分区：
文献类型：
--
作者：
Alicic, Radica Z.;Johnson, Emily J.;Tuttle, Katherine R.
糖尿病肾病（DKD）是全球CKD和终末期肾病（ESKD）的主要原因。大约30-40%的糖尿病患者会发生这种微血管并发症，使他们面临肾功能丧失以及心血管事件、感染和死亡的高风险。目前的治疗对于阻止DKD患者的肾脏疾病进展和减轻合并症和死亡风险无效。随着全球糖尿病患者人数即将超过4亿，对DKD等并发症的有效和安全治疗选择的需求变得更加迫切。最近，对DKD发病机制的理解已经发展到认识到炎症是肾损伤的主要潜在机制。反过来，炎症介质已成为DKD的潜在生物标志物和治疗靶点。检测单核细胞趋化蛋白-1趋化因子C-C基序-配体2和Janus激酶/信号转导子和转录激活子途径抑制剂的2期临床试验已产生了有希望的结果。(C)2017年由国家肾脏基金会，Inc. All rights reserved.
Diabetic kidney disease (DKD) is the leading cause of CKD and end-stage kidney disease (ESKD) worldwide. Approximately 30-40% of people with diabetes develop this microvascular complication, placing them at high risk of losing kidney function as well as of cardiovascular events, infections, and death. Current therapies are ineffective for arresting kidney disease progression and mitigating risks of comorbidities and death among patients with DKD. As the global count of people with diabetes will soon exceed 400 million, the need for effective and safe treatment options for complications such as DKD becomes ever more urgent. Recently, the understanding of DKD pathogenesis has evolved to recognize inflammation as a major underlying mechanism of kidney damage. In turn, inflammatory mediators have emerged as potential biomarkers and therapeutic targets for DKD. Phase 2 clinical trials testing inhibitors of monocyte-chemotactic protein-1 chemokine C-C motif-ligand 2 and the Janus kinase/signal transducer and activator of transcription pathway, in particular, have produced promising results. (C) 2017 by the National Kidney Foundation, Inc. All rights reserved.